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The African Green Monkey (AGM) model was used to analyze the role of complement in neutralization of
parainﬂuenza virus. Parainﬂuenza virus 5 (PIV5) and human parainﬂuenza virus type 2 were effectively
neutralized in vitro by naïve AGM sera, but neutralizing capacity was lost by heat-inactivation. The
mechanism of neutralization involved formation of massive aggregates, with no evidence of virion lysis.
Following inoculation of the respiratory tract with a PIV5 vector expressing HIV gp160, AGM produced
high levels of serum and tracheal antibodies against gp120 and the viral F and HN proteins. However, in
the absence of complement these anti-PIV5 antibodies had very poor neutralizing capacity. Virions
showed extensive deposition of IgG and C1q with post- but not pre-immune sera. These results highlight
the importance of complement in the initial antibody response to parainﬂuenza viruses, with
implications for understanding infant immune responses and design of vaccine strategies for these
pediatric pathogens.
& 2014 Elsevier Inc. All rights reserved.
Introduction
The complement system is an important component of the
innate immune response to viruses. Complement (C') antiviral
functions include a large number of activities, including recogni-
tion of viruses and virus-infected cells, direct neutralization of
virus infectivity, recruitment and stimulation of leukocytes at sites
of infection, phagocytosis by immune cells, and activation of
antiviral T and B cells (Blue et al., 2004; Gasque, 2004; Kemper
and Atkinson, 2007). Likewise, viruses employ mechanisms to
limit C' functions (e.g., Blue et al., 2004; Johnson et al. 2012). The
balance between C' effectiveness and virus inhibition of C' can
have important implications for viral pathogenesis and dissemina-
tion (Delgado and Polack, 2004; Morrison et al., 2007, Stoermer
and Morrison, 2011). C' can also directly impact adaptive immunity
(Carroll, 2004; Kemper and Atkinson, 2007) and can inﬂuence
the quality of anti-viral antibody responses (Pierson et al., 2008).
The overall goal of the work described here was to determine the
contribution of C' to the neutralizing capacity of antibodies elicited
by respiratory tract infection of nonhuman primates with parain-
ﬂuenza virus.
The C' proteolytic cascade can be initiated through three main
pathways: the classical pathway, lectin pathway and alternative
pathway (Gasque, 2004; Roozendaal and Carroll, 2006). Activation
of the classical pathway typically involves binding of the C1q
component to virus-antibody complexes. Human Immunodeﬁ-
ciency Virus (HIV; Ebenbichler et al., 1991) and vesicular stomatitis
virus (VSV; Beebe and Cooper, 1981) are known to activate the
classical pathway. The lectin pathway is activated through recog-
nition of carbohydrate signatures on viral glycoproteins by the
cellular mannan-binding lectin (MBL). This is an important path-
way in the pathogenesis of Ross River Virus (Gunn et al., 2012) and
in the opsonization of inﬂuenza virus (Hartshorn et al., 1993).
Compared to activation of the classical and lectin pathways, the
signals that activate the alternative pathway are less well under-
stood, but they are thought to involve recognition of foreign
surfaces by an antibody-independent mechanism (Gasque, 2004;
Pangburn et al., 1981).
Parainﬂuenza virus 5 (PIV5), human parainﬂuenza virus 2
(HPIV2) and mumps virus (MuV) are closely-related negative
strand RNA viruses belonging to the rubulavirus genus of the
paramyxovirus family (Lamb and Parks, 2013; Parks et al. 2011).
Prior work has shown that the rubulavirus attachment protein
(Hemagglutinin-Neuraminidase; HN) and the fusion protein
(F) can both contribute to activation of the alternative pathway
(McSharry et al., 1981; Hirsch et al., 1986; Johnson et al., 2008;
2013). For PIV5 and MuV, the extent of alternative pathway
activation is directly related to the loss of sialic acid on particles
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due to the presence of neuraminidase activity in the HN protein
(McSharry et al., 1981; Hirsch et al., 1986). Furthermore, the
rubulavirus F protein can dictate which arm of the C' pathway is
activated. This was evident by our recent ﬁnding that a single
point mutation in the ectodomain of the PIV5 F protein led to
increased fusion activity, but also led to enhanced binding of IgG
contained in normal human sera (NHS) and a subsequent shift in
C' activation from the alternative to the classical pathway (Johnson
et al., 2013).
Once activated, C' components are capable of direct neutraliza-
tion of viruses, through mechanisms that can include aggregation
or virion lysis (Blue et al., 2004; Stoermer and Morrison, 2011).
In addition, C' can enhance the neutralizing capacity of antibodies
(Mehlhop et al., 2009). For HPIV2, our prior results demonstrated
very high levels of neutralizing antibody in NHS (Johnson et al.,
2008), making the contribution of C' to neutralization difﬁcult to
analyze. In addition, repeated exposure to parainﬂuenza virus as
infants (Karron and Collins, 2013) and the use of adult NHS in
neutralization assays makes it difﬁcult to determine the role of C'
in the antibody function following the very ﬁrst exposure at an
early age to human parainﬂuenza virus infection. By contrast, we
have previously shown in reconstitution experiments that PIV5 is
neutralized through pathways that are highly dependent on the
alternative C' pathway (Johnson et al., 2008). These mechanisms
are either independent of antibody or involved antibodies in NHS
that are only highly effective when coupled with C'.
Given the importance of understanding the initial immune
response to parainﬂuenza virus infections, we have examined the
role of C' in a primary PIV5 respiratory tract infection of African
Green Monkeys (AGM), an increasingly important model system
for understanding primate immunology (Messaoudi et al., 2011).
The animals used in this study were part of a multigenerational,
pedigreed, and genotyped Vervet Research Colony (VRC) at the
Wake Forest University Primate Center (described in Jasinska et al.,
2012). A powerful aspect of using this AGM system lies in the
ability to measure the effect of C' on parainﬂuenza virus immunity
in both naïve and vaccinated animals with immune systems that
are closely related to that of humans. We show that respiratory
tract infection of AGM with PIV5 elicits high levels of antibodies to
viral antigens. However, these antibodies have poor inherent
neutralizing capacity and are highly dependent on C' pathways.
Our results have implications for including C' pathways as a major
contributing factor in analysis of the potency of immune responses
to parainﬂuenza virus infections and vaccine vectors.
Results
Normal monkey serum has potent neutralizing capacity against
PIV5 and HPIV2
To determine the ability of normal African Green monkey
serum (NAGS) to neutralize PIV5 in vitro, serum samples were
collected from 20 AGM and used in neutralization assays with
100 PFU of PIV5-GFP. After 1 h at 37 1C, remaining infectivity was
determined by plaque assay. As shown in Fig. 1A for representative
sera from eight individual monkeys, a 1/20 dilution of NAGS
reduced PIV5 infectivity to undetectable levels. In contrast, HI
AGM serum was ineffective in neutralization. Titration experi-
ments (Fig. 1B) showed effective neutralization of PIV5 by at least a
1:160 dilution of NAGS, but HI serum had no neutralizing capacity.
Similar results were seen with neutralization of HPIV2 by NAGS
(Fig. 1C). These results indicate that in the absence of C', NAGS
from the WFU VRC have low capacity to neutralize these two
parainﬂuenza viruses.
C'-mediated neutralization with NAGS could occur by lysis of
virion particles (e.g. as seen with VSV; Johnson et al., 2012) or by
formation of large aggregates (e.g., PIV5; Johnson et al., 2008).
To determine the mechanism of PIV5 neutralization by NAGS,
puriﬁed virus was incubated in solution at 37 1C alone or with a
1:20 dilution of NAGS before applying to a grid for analysis by
electron microscopy. As shown in Fig. 1D, treatment of PIV5
particles with NAGS resulted in the formation of massive aggre-
gates (note scale bar in panels), with little evidence of virus lysis.
As a control, treatment of vesicular stomatitis virus with human
sera resulted in virion lysis as evident by the detection of
nucleocapsid structures (Fig. 1D). Thus, like human sera (Johnson
et al. 2008), the potent C'-dependent neutralization of PIV5 by
NAGS is through a mechanism involving aggregate formation.
Antibodies do not contribute to C'-mediated neutralization of PIV5
by naïve NAGS
To determine if the animals used in this study had detectable
levels of anti-PIV5 antibodies, mock infected or PIV5-infected
A549 cells were analyzed for cell surface staining by NAGS.
As shown in Fig. 2A, the positive control polyclonal anti-PIV5 mouse
serum gave strong cell surface staining on PIV5 infected cells. As
shown for one representative animal (Fig. 2A; animal #1484), the
NAGS from animals used in this study showed no signiﬁcant staining
on PIV5-infected cells compared to mock infected controls. Using
western blotting of lysates from mock infected and PIV5-infected
cells, sera from a few animals showed very low level reactivity
against N protein (star, Fig. 2B). However, similar to the results from
the immunoﬂuorescence analysis, there was no detectable signal for
reactivity against the viral glycoproteins.
To directly test the role of antibodies in PIV5 neutralization by
naïve animals, NAGS was depleted of IgG by treatment with
Protein G-sepharose or with sepharose alone as a control and
then tested for their capacity to neutralize PIV5-GFP in vitro.
As shown in Fig. 2C, a 1:20 dilution of NAGS was equally effective
in neutralizing PIV5-GFP when left untreated or following treat-
ment with Protein G-sepharose or control sepharose lacking
Protein G. Together, these data support the proposal that the
animals used in this study lack substantial levels of antibodies to
the PIV5 glycoproteins which could contribute to neutralization,
and that the C'-mediated neutralization shown above in Fig. 1 is
through an antibody-independent mechanism.
A recombinant PIV5 expressing HIV gp160 elicits strong serum
antibody titers to PIV5 antigens and gp120
To determine the ability of a PIV5 vector to elicit antibody
responses to viral and vector-encoded antigens in AGM, PIV5 was
engineered to express the HIV IIIB gp160 protein as an additional
gene between HN and L (Fig. 3A). Cells infected with the PIV5-
gp160 vector expressed high levels of gp160 as detected by
western blotting (Fig. 3B). Analysis of multi-step growth in tissue
culture cells showed that the PIV5-gp160 virus grew slightly
slower than the control PIV5-GFP (Fig. 3C), but this difference
was less apparent in analysis of single step growth (high moi).
To determine the capacity of PIV5-gp160 to elicit antibody
responses, four adult 3 year old AGM were innoculated (in two
separate experiments using two animals each) by both the
intranasal and intratracheal routes with 108 PFU of puriﬁed virus.
Tracheal washes were obtained on d4 and d8, and serum was
collected on d7 and d14 post inoculation. Throughout the time-
course of the experiment, animals showed no signs of overt illness,
as evidenced by the lack of signiﬁcant rise in temperature, no loss
of cognitive function and the absence of labored breathing (data
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not shown). Analysis of tracheal wash ﬂuid by TCID50 assay did not
reveal detectable virus shedding at any time tested.
Pre-immune and d14 post-innoculation sera were analyzed by
ELISA for anti-PIV5 antibodies as described previously (Johnson
et al., 2008). As shown by the representative data for monkeys
1515 and 1536 in Fig. 4A, inoculated AGM generated anti-PIV5 IgG
and IgM levels that were detectable above that seen with control
preimmune sera out to 1:200,000 and 1:12,800, respectively.
Titers expressed as the reciprocal of the dilution of sera giving
50% of maximum absorbance ranged from 31,000 to 70,000 for IgG
and 2200 to 4800 for IgM (Fig. 4B). Similarly, serum antibodies
against gp120 were detected above that seenwith a control animal
serum, although titers were not as high as that seen against PIV5
antigens and were less consistent between animals (Fig. 4A).
Tracheal lavage samples from the inoculated AGM were tested
for the presence of mucosal-associated anti-PIV5 IgG and IgM.
As shown for animals 1515 and 1536 in Fig. 4C, levels of IgG at d4
post inoculation were detectable above control levels, but were
substantially higher at d8 post inoculation. Tracheal lavage sam-
ples also contained anti-gp160 IgG (Fig. 4C) and IgM (not shown),
although the titers were apparently much lower than that of the
anti-PIV5 antibodies. These data indicate that innoculation of the
AGM respiratory tract with PIV5-gp160 elicits strong systemic and
mucosal antibody responses.
Effective neutralization of PIV5 with post-infection AGM sera requires
intact C' pathways
The capacity of AGM antibodies to neutralize PIV5 was tested
by incubating dilutions of pre- and post-infection sera with PIV5-
GFP and determining remaining infectivity by plaque assay.
In addition, HI sera was analyzed to deﬁne the role of C’ in
neutralization. As shown in the example in Fig. 5A for sera from
animal #1690, pre-immune and d7 sera were effective in neutra-
lization 80% of infectivity at a 1:40 dilution, but was no longer
effective after HI treatment. By contrast, d14 serum was highly
effective in neutralizing PIV5, with no detectable infectivity seen
out to a 1:200 dilution. Unexpectedly, HI removed much of the
potency of neutralization by post-immune sera, since a 1:200
dilution of HI serum only neutralized 20% of infectivity. Similar
results were seen for all four PIV5-innoculated animals. For
example, as shown in Fig. 5B, d14 post-immune sera from
monkeys #1515 and #1536 were highly effective in neutralizing
PIV5 out to at least a 1:200 dilution. However, after HI treatment
both of these post-immune sera were only capable of substantial
neutralization out to 1:20. When higher dilutions of d14 post-
immune sera were tested (Fig. 5C), PIV5 was neutralized at
dilutions greater than 1:800. Final titers expressed as the recipro-
cal of the dilution of sera giving 50% neutralization ranged from
684, 842, 728 and 819 for animals 1515, 1536, 1685 and 1690,
respectively. Together, these data indicate that the potency of d14
anti-PIV5 neutralizing antibodies is greatly reduced when sera are
HI, indicating a high dependence on active C' pathways.
C1q is part of the C1 complex, which is necessary for and speciﬁc
to the classical pathway. To test the hypothesis that post-immune
AGM serum utilizes the classical pathway to neutralize PIV5, puriﬁed
PIV5 particles were incubated with either pre-immune or post-
immune serum. C1q and IgG deposition were each detected using
gold bead labeling. PIV5 particles treated with pre-immune serum had
no detectable IgG or C1q deposition (Fig. 6A). In contrast, high levels of
both IgG (6 nm beads; small arrow) and C1q (12 nm beads; white
arrow) were detected on the surface of PIV5 particles treated with
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Fig. 1. NAGS has potent C'-mediated neutralizing capacity against parainﬂuenza virus. (A) One hundred PFU of PIV5-GFP were incubated for 1 h at 37 1C with media alone
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post-immune sera (Fig. 6B). These data support the proposal that
antibodies elicited at d14 post-infection are highly dependent on C' for
PIV5 neutralization, and proceed through the classical antibody-
triggered pathway. This ﬁnding also conﬁrms that pre-immune NAGS
does not neutralize by the classical pathway, as there was no Ig or C1q
deposition on virus particles treated with pre-immune serum.
To determine the mechanism of neutralization by post-immune
AGM serum, puriﬁed PIV5-GFP was treated with post-immune
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sera and at different times analyzed by EM. As shown in Fig. 6C
for a representative monkey sample, serum-treated virions held
on ice showed a mixture of dispersed particles as well as some
aggregation. However, after as little as 15 min at 37 1C, virions
were only seen in massive aggregates with very little evidence
of virion lysis (see size of bar in Fig. 6D, and expanded view of
aggregate, Fig. 6E). Thus, post-immune sera (Fig. 6) and pre-
immune sera (Fig. 1) both neutralize PIV5 by aggregation, with
the major difference being the more rapid aggregation seen by
post-immune sera.
AGM inoculated with PIV5 produce strong antibody responses to both
F and HN proteins
One possible explanation for the high dependence of post-
immune sera on C' for neutralization is that the inoculated AGM
did not produce antibodies to both F and HN. To determine which
viral proteins are recognized by post-immune AGM antibodies,
Hep2 cells were mock infected or infected with PIV5 and lysates
were analyzed by western blotting. As shown in Fig. 7A, two major
viral proteins were speciﬁcally recognized by post-immune serum
and alignment with known viral proteins indicated these were NP
and P protein. No detectable signs of reactivity with SDS-denatured
F, HN or M proteins were seen.
To determine if post-immune sera recognized F and HN
expressed on the cell surface, cells were mock infected or infected
with PIV5, or with recombinant vaccinia virus (VacV) expressing
either F protein, HN protein or the control protein ovalbumin. Cells
were examined for surface staining by post-immune sera followed
by FITC-conjugated goat anti-monkey IgG. As seen in Fig. 7B for
representative serum from monkey 1515, antibodies recognized
PIV5-infected cells but importantly also speciﬁcally recognized
cells infected with both VacV-F and VacV-HN. Thus, antibodies to
both of the two major PIV5 glycoproteins are present in AGM post-
immune sera, but their capacity to neutralize virus is highly
dependent on intact C’ pathways.
PIV5 derived from AGM cells is refractory to neutralization by NAGS
The above data were generated using PIV5 grown in the bovine
cell line MDBK, the standard cell type for generation of PIV5
stocks. To determine if PIV5 grown in AGM versus bovine cells
differed in neutralization by non-immune NAGS, PIV5 was grown
in the AGM cell line CV1 or MDBK cells and C'-mediated neutra-
lization was carried out. As shown in Fig. 8 for two representative
naïve NAGS samples, MDBK-derived virus showed effective
C'-dependent neutralization by as high as 1:80 dilution of serum.
CV1-derived virus was also neutralized by NAGS, but effective
neutralization was not seen at higher dilutions. These data are
consistent with the proposal that host cell-derived inhibitors
of C' are incorporated into paramyxovirus particles (Johnson
et al., 2012), and that they block C' pathways in a species speciﬁc
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manner. Most importantly for this study, the ﬁnding that AGM-
derived PIV5 is more resistant to C' neutralization by NAGS further
highlights the importance of C' in determining the potency of
antibodies that are elicited during an infection by parainﬂuenza
viruses.
Discussion
Antibodies can be an important factor in the neutralization of
many of the paramyxoviruses associated with pediatric respiratory
tract infections (e.g., Delgado and Polack, 2004; Karron and Collins,
2013). However, the contribution of C' to the potency of the
antiviral antibodies that are elicited following a primary parain-
ﬂuenza virus infection is often overlooked or difﬁcult to analyze.
This is in large part due to the very high levels of pre-existing
parainﬂuenza virus antibodies in human sera following repeated
exposure at an early age and also due to the use of adult versus
infant sera in many analyses of virus neutralization. Here we have
used a nonhuman primate model system to determine the con-
tribution of C' to the neutralizing capacity of antibodies that are
elicited following the ﬁrst exposure to PIV5 infection of the
respiratory tract. In the animal population used for this study,
we found no evidence for pre-existing PIV5 glycoprotein-speciﬁc
antibodies, and depletion of antibodies from non-immune serum
did not alter C'-mediated neutralization of PIV5. Our most striking
ﬁnding was that respiratory tract infection elicited strong anti-
PIV5 antibodies when assayed by ELISA and these antibodies
included responses to both F and to HN, but the neutralizing
capacity of these antibodies was highly dependent on intact
C' pathways. Further support for C'-dependence in neutralization
by post-immune sera came from the ﬁnding that PIV5 virions
exhibit strong C1q and IgG deposition when treated with post- but
not pre-immune sera. As described below, these results have
implications for the potential to harness C' functions to enhance
early immune responses to paramyxovirus infections.
Our ﬁnding that anti-PIV5 antibodies have high C' dependence
could reﬂect the need to generate neutralizing antibodies that are
speciﬁc for the native form of the parainﬂuenza virus glycopro-
teins. It is known that antibodies to both HN and F are elicited by
parainﬂuenza virus infection and they both can contribute to
immunity (Karron and Collins, 2013; Spriggs et al., 1987). In the
speciﬁc case of PIV5, previous work in a hamster model with
recombinant VacV expressing F or HN showed that vaccination
with F alone generated higher antibody levels than vaccination
with HN alone, but anti-HN antibodies were more protective in
challenge experiments (Paterson et al., 1987). However, the con-
tribution of C' to these immune responses and protection was not
tested. It is known that there are substantial structural differences
between immature and mature forms of the viral glycoproteins
(Lamb and Jardetzky, 2007; Mottet et al., 1986). Likewise, point
mutations that destabilize the F protein can alter the binding of
human antibodies and increase dependence on C' for neutraliza-
tion (Johnson et al., 2013). Thus, the inherent conformation of the
parainﬂuenza glycoproteins and epitope accessibility due to virion
structures could be a major factor in eliciting antibodies that are
initially of low avidity and more dependent on C' for neutraliza-
tion. This is consistent with prior proposals that the structure of
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Fig. 5. Effective neutralization of PIV5 with post-infection AGM sera requires intact C' pathways. (A and B) PIV5-GFP was incubated with PBS (control, Ctr, gray bar) or with
the indicated dilutions of normal or HI preparations of pre-immune, d7 post-immune or d14 post-immune sera from animals 1690 (panel A) or 1515 and 1536 (panel B).
Remaining infectivity was determined by plaque assay. Results represent the average of four assays, with error bars representing standard deviations. (n) No plaques were
detected in these samples. (C) PIV5-GFP was incubated with the indicated dilutions of d14 post-immune sera from the four AGM and samples were analyzed as described for
panels A and B.
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enveloped virus particles can contribute to differential C' depen-
dence for neutralization, since antibodies against the VacV extra-
cellular enveloped form are highly dependent on C' for activity
(Benhnia et al., 2009),
Alternatively, the high C'-dependence of antibodies generated
in our model system could be a reﬂection of the particular animals
used in our study. The WFU VRC was founded in 1975 with 57
animals imported from the islands of St. Kitts and Nevis (described
in Jasinska et al., 2012). Since the mid-1980s, this has been a closed
animal breeding colony, with no new animals imported since that
time. Previous work on parainﬂuenza virus infection of AGM (e.g.,
Schaap-Nutt et al., 2011) showed that animals elicited strong levels
of serum antibodies, but the origin of the animals used in these
studies was not detailed. Thus, the restricted breeding within a
closed colony such as the WFU VRC may contribute to genetic
bottlenecks in the ability to generate a range of antibodies that
have varying degrees of dependence on C'. The ability to exploit
the documented pedigree of the VRC (Jasinska et al., 2012) and the
availability of complete genome sequences for many of these
animals (http://www.genomequebec.mcgill.ca/compgen/vervet_
research/) provides an opportunity to explore the role of genetics
in C' dependence for neutralization.
Our results are based on immune responses elicited following
an initial experimental exposure of animals to PIV5, and have not
included an analysis of neutralizing capacity following a secondary
exposure or boost. For the closely related MuV, human antibodies
elicited by early exposure are initially of low afﬁnity and limited
isotype diversity, but the antibodies appear to have higher afﬁnity
and broader isotype proﬁles after re-exposure (reviewed in Rubin
and Vandermeulen, 2011). Thus, future studies with prime-boost
protocols could reveal that high dependence on C' for neutraliza-
tion is a reﬂection of the primary exposure to virus infection. This
would be consistent with results with mouse antibodies raised to
inﬂuenza virus, where C' effects were primarily seen the case of
the antibodies elicited by primary exposure (Feng et al., 2002).
We found that the mechanism of PIV5 neutralization by naïve
non-human primate serum was C'-dependent but antibody-inde-
pendent, and proceeded through formation of massive aggregates,
similar to that seen with human sera (Johnson et al., 2008).
A similar result was reported for inﬂuenza virus, where serum
samples from inﬂuenza-naïve mice neutralized inﬂuenza virus
particles by forming viral aggregates, though neither natural IgM
nor C' alone was sufﬁcient for neutralization (Jayasekera et al.,
2007). Thus, in contrast to other negative strand RNA viruses such
as VSV and HPIV3 which show C'-dependent virion lysis (Johnson
et al., 2012; Vasantha et al., 1988), there was no evidence that
exposure to AGM serum resulted in release of PIV5 nucleocapsids
from within the lipid envelope. Importantly, sera from inoculated
animals also neutralized PIV5 through this common mechanism,
with the only discernable difference between pre- and post-
immune sera being the kinetics of virus aggregation. It is not clear
why, despite strong activation of C', the pathway does not progress
to virion lysis. This could reﬂect failure to progress through the
C' pathway to MAC formation or lack of a functional membrane
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Fig. 6. C1q and IgG deposition on puriﬁed PIV5 after treatment with pre- and post-immune sera. (A and B) Puriﬁed PIV5-GFP was treated with a 1/20 dilution of either pre-
(panel A) or post-immune (panel B) monkey sera. Samples were subsequently treated with gold-conjugated anti-C1q (12 nm beads) and anti-human IgG (6 nm beads).
Samples were analyzed by EM at a magniﬁcation of 68,000 . (C and D) Puriﬁed PIV5-GFP was incubated with a 1:20 dilution of post-immune sera on ice for 1 min (Panel C;
49,000 ) or for 15 min at 37 1C (panel D; 18,000 ) and then analyzed by electron microscopy. The size of bars is indicated. The black box in panel D indicates the area
expanded in the 0.5 mm image.
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attack complex (MAC) due to the presence of C' inhibitors within
the virion (Johnson et al., 2013).
Since treatment of PIV5 with post-immune sera does not result
in virion lysis, how does C' enhance the neutralizing potency of
monkey anti-PIV5 antibodies? Mehlhop et al. (2009) have shown
for WNV that C1q was able to lower the threshold number of
anti-viral antibodies that are needed for neutralization, and it was
proposed that this enhancement was due to changes in epitope
accessibility. Thus, C' factors may alter epitope accessibility of
otherwise weakly neutralizing antibodies. Importantly, the con-
tribution of C' factors to enhanced antibody function in the case of
WNV and inﬂuenza virus was highly dependent on antibody
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Fig. 7. PIV5 proteins recognized by antibodies in sera from PIV5-innoculated AGM. (A) Lysates from Hep2 cells mock infected (M lanes) or infected (I lanes) with PIV5-GFP
were analyzed by western blotting using sera from infected AGM animal numbers 1515 and 1536. Control blots that were probed with mono-speciﬁc rabbit anti-sera to NP, P
or M proteins served as markers for the position of viral proteins. (B) CV-1 cells were mock infected or infected at an moi of 10 with PIV5 or with VacV individually expressing
PIV5 F, PIV5 HN or control ovalbumin. Cells were ﬁxed and analyzed for surface staining with monkey 1515 post-immune sera.
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Fig. 8. PIV5 derived from AGM cells is resistant to C'-mediated neutralization. One hundred twenty PFU of PIV5-GFP grown in MDBK or CV-1 cells were incubated for 1 h at
37 1C with media alone (control Ctr; left gray bar) or with the indicated dilutions of NAGS (striped bars) or 1:40 of heat inactivated serum (HI, black bars). Remaining
infectivity was determined by plaque assays. Results represent the average of four assays, with error bars representing standard deviations. (n) No plaques were detected in
these samples.
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subclass (Feng et al., 2002; Mehlhop et al., 2009). This raised the
critical point that vaccination strategies designed to induce
C'-activating antibodies (e.g., human IgG1 and IgG3) should result
in more robust protective responses.
PIV5 is being developed by a number of research groups as a
promising vaccine or therapeutic vector (Clark et al., 2011; Chen
et al., 2013; Gainey et al., 2008; Tompkins et al., 2007). Consistent
with this, AGM inoculated with PIV5-gp160 elicited anti-gp120 IgG
and IgM both systemically as well as at the mucosal surface
of the respiratory tract. In each of the model systems we have
employed – including mice, ferrets and nonhuman primates –
inoculation of animals with PIV5 does not result in overt disease
symptoms, including no respiratory distress, elevation of tempera-
ture, or other signs of disease. It is also noteworthy that animals
either previously vaccinated with PIV5 vectors or with natural pre-
existing anti-PIV immunity can still respond extremely well to a
secondary vaccination with the same PIV5 (Capraro et al., 2008;
Chen et al., 2012). Our ﬁnding here that anti-viral antibodies
elicited by the ﬁrst respiratory tract exposure to PIV5 are inher-
ently weakly-neutralizing may provide an explanation for this,
since the existing antibodies alone may not be able to prevent
reinfection.
It is known that human C' activity is low in neonates and
infants when compared to adults. For example, the concentrations
of many C' factors in cord blood and in newborns have been
estimated to be only 10–80% that of adults. Additionally, the
functional activity of factors in the neonate C' cascade is thought to
be much lower than can be accounted for by concentration alone
(McGreal et al., 2012; Zach and Hostetter, 1989). Given the
importance of respiratory tract infections of infants and children
(Karron and Collins, 2013), our results highlight the importance of
understanding the role of C' in the initial antibody response of
infants to parainﬂuenza virus natural infections as well as the
development of protective vaccines against these and other
viruses (Hodgins and Shewen, 2012).
Materials and methods
Cells and viruses
Monolayer cultures of A549, CV-1, MDBK, and Hep2 cells were
grown in Dulbecco modiﬁed Eagle medium (DMEM) supplemen-
ted with 10% HI fetal bovine serum (FBS), penicillin (100 units/ml),
streptomycin (100 mg/ml) and 200 mM L-Glutamine. U937 cells
were grown in RPMI supplemented as above. Recombinant PIV5
isolates were grown in MDBK cells. HPIV2 was grown and titered
in CV-1 cells. Viruses were concentrated by centrifugation through
a glycerol cushion (5 h; 25,000 RPM; SW28 rotor), and resus-
pended virus was further puriﬁed by centrifugation on a 30–60%
sucrose gradient (2 h; 23,000 RPM; SW28 rotor). The virus band
was collected, pelleted again, resuspended in PBS containing 0.75%
BSA and stored at 80 1C.
WT PIV5 encoding the GFP gene between HN and L (PIV5-GFP)
has been described (He et al., 1997). To generate a cDNA encoding
PIV5-gp160, the gene encoding the BH8 HIV-1 gp160 protein was
removed from plasmid pPE5 (Earl et al., 1990) and altered by PCR
to encode 50 EcoRV and 30 SalI sites. The resulting DNA fragment
was digested with these two enzymes and inserted into the StuI
and SalI sites of a modiﬁed version of pBH276 (He et al., 1997).
Recombinant PIV5 was recovered from transfected cells as
described previously (Parks and Alexander-Miller, 2002).
Concentration-dependent virus neutralization by normal sera
and HI sera was carried out in 200 ul reactions for 1 h at 37 1C as
previously described (Johnson et al., 2012), with remaining infec-
tivity determined by plaque assay on CV-1 cells. Results are the
average of four to six reactions, with the signiﬁcance of data points
calculated using the student's t-test. Antibodies were depleted
from NAGS by treatment of a 1:20 dilution of NAGS with 50 ml of
Protein G-sepharose on ice for 15 min. Samples were then used in
neutralization assays as described above.
Animal procedures
All procedures were approved by the Wake Forest University
Animal Care and Use Committee. Procedures were based on
published approaches for infection of AGM with HPIV2 (Schaap-
Nutt et al., 2011). Healthy 3 year-old African Green Monkeys
(Chlorocebus aethiops) were sedated with ketamine, and placed
in a dorsal position before receiving 108 PFU of puriﬁed PIV5-
gp160 delivered in a total of 2 ml of sterile PBS. One milliliter was
delivered to the trachea and 0.5 ml was delivered to each nostril.
Animals were monitored for resting respiration rate, attitude, and
signs of respiratory disease. To collect BAL, 15 ml of sterile PBS was
administered into the trachea followed by a 15 ml bolus of air. PBS
was then aspirated with a syringe, adjusted to 0.5% bovine serum
albumin and stored at 80 1C. Blood was collected by femoral
venipuncture at the days pi indicated in the ﬁgure legends and
allowed to clot for 1 h at 37 1C. The clot was retracted and serum
was separated by centrifugation, aliquoted and stored at 80 1C.
Complement inactivated serum was prepared by heating NAGS at
56 1C for 30 min.
ELISA
Anti-PIV5 ELISAs were performed as described previously
(Johnson et al., 2008). Brieﬂy, MaxiSorp 96-well ELISA plates
(Nunc) were coated with 1 mg of sucrose gradient-puriﬁed PIV5.
For gp160 ELISAs, plates were coated with 0.2 mg of recombinant
gp120 (reagent 11784 supplied by NIH AIDS Research and Refer-
ence Program). Plates were incubated at 4 1C overnight, washed
three times with PBS/Tween (0.2%), and wells were blocked with
200 ml of PBS containing 2% BSA for 2 h at room temperature.
Dilutions of sera were added to wells, incubated for 1 h, and wells
were washed with PBS/Tween before incubation for 1 h with HRP-
conjugated goat anti-monkey IgG or IgM (Jackson ImmunoRe-
search Laboratories, PA) and development with substrate TMB
(tetramethylbenzidine dihydrochloride, Sigma). The absorbance
was determined at 450 nm on a Labsystems Multiskan Plus plate
reader (Fisher Scientiﬁc, GA).
Electron microscopy
To visualized virions, puriﬁed PIV5 particles were mixed with
NAGS at a dilution of 1:20 and incubated in ﬂuid phase for various
time points (0, 15, 30 and 60 min) at 37 1C followed by addition of
the samples onto carbon coated 200 mesh gold Formvar carbon
support grids (catalog number CF200-AU; Electron Microscopy
Sciences, Hartﬁeld, PA). After adsorption for 10 min, grids were
ﬁxed with 2.5% glutaraldehyde, washed with PBS, negatively
stained with 2% phosphotungstic acid and observed under a
Technai transmission electron microscope. Alternatively, virions
were treated with NAGS (1:20 dilution), blocked with 1% BSA in
PBS and then probed with anti-C1q or anti-human IgG polyclonal
antibody at a 1:25 dilution PBS with 1% BSA. C1q deposition was
detected with 12 nm gold-labeled donkey anti-goat antibody
(Jackson Immunoresearch Laboratories, PA). Binding of human
antibody was analyzed using 6 nm gold-labeled goat anti-human
secondary antibody.
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Western blotting and immunoﬂuorescense
Western blotting was carried out as described previously using
either AGM sera or mono-speciﬁc rabbit antisera to the PIV5 P, M
and NP proteins (Parks and Alexander-Miller, 2002). Alternatively,
blots were probed with goat anti-gp120 polyclonal antibody (US
Biologicals catalog number H6003-35). Blots were visualized by
enhanced chemiluminescence and exposure to ﬁlm.
Immunoﬂuorescence was carried out as described previously
(Manuse and Parks, 2009). Brieﬂy, CV-1 cells infected at an moi of
10 with PIV5, or with recombinant vaccinia viruses expressing the
PIV5 F, PIV5 HN (Paterson et al., 1987) or control ovalbumin (Parks
and Alexander-Miller, 2002). At 18 h pi, cells were ﬁxed in
paraformaldehyde, and stained with a 1:500 dilution of monkey
post-immune sera followed by a 1:1000 dilution FITC-conjugated
goat anti-monkey IgG (Serotec). As a positive control, mouse
polyclonal anti-PIV5 serum was generated by intranasal infection
of Balb/c mice with PIV5 and collection of sera at day 28 post-
infection. Images were captured using QImaging digital camera
and processed using Q-capture software. Exposure times were
manually set to be constant between samples.
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